cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Newlink Genetics Corporation
3 own
3 watching
Current Price
$3.4
$-0.03
(-0.87%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
28.48M
52-Week High
52-Week High
10.27
52-Week Low
52-Week Low
2.95
Average Volume
Average Volume
0.05M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization28.48M
icon52-Week High10.27
icon52-Week Low2.95
iconAverage Volume0.05M
iconDividend Yield--
iconP/E Ratio--
What does the Newlink Genetics Corporation do?
Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.
Read More
How much money does Newlink Genetics Corporation make?
News & Events about Newlink Genetics Corporation.
Globe Newswire
1month ago
12th Annual Corporate Access Event Register for in-person meetings with Lumos Pharma AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.(NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2...
Globe Newswire
1month ago
AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6th to review the Companys interim data from two Phase 2 ...
Ticker Report
2 months ago
Lumos Pharma (NASDAQ:LUMO Get Rating) had its price target decreased by Oppenheimer to $18.00 in a research note issued to investors on Thursday morning, Stock Target Advisor reports. Oppenheimer also issued estimates for Lumos Pharmas FY2022 earnings at ($3.71) EPS, Q2 2023 earnings ...
Zolmax
2 months ago
Lumos Pharma (NASDAQ:LUMO Get Rating) had its price target decreased by Oppenheimer to $18.00 in a research note issued to investors on Thursday morning, Stock Target Advisor reports. Oppenheimer also issued estimates for Lumos Pharmas FY2022 earnings at ($3.71) EPS, Q2 2023 earnings at ($1.06) EPS...
Globe Newswire
5 months ago
AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.(NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on...
Frequently Asked Questions
Frequently Asked Questions
What is Newlink Genetics Corporation share price today?
plus_minus_icon
Can Indians buy Newlink Genetics Corporation shares?
plus_minus_icon
How can I buy Newlink Genetics Corporation shares from India?
plus_minus_icon
Can Fractional shares of Newlink Genetics Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in Newlink Genetics Corporation stocks?
plus_minus_icon
What is today’s traded volume of Newlink Genetics Corporation?
plus_minus_icon
What is today’s market capitalisation of Newlink Genetics Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of Newlink Genetics Corporation?
plus_minus_icon
What percentage is Newlink Genetics Corporation down from its 52-Week High?
plus_minus_icon
What percentage is Newlink Genetics Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$3.4
$-0.03
(-0.87%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
MEDAVAIL HOLDINGS INC
MEDAVAIL HOLDINGS INC
$0.39
$0.01 (1.32 %)
Finch Therapeutics Group Inc
Finch Therapeutics Group Inc
$0.50
$-0.01 (-2.13 %)
Humanigen Inc
Humanigen Inc
$0.23
$0.00 (2.06 %)
Immutep Ltd
Immutep Ltd
$1.90
$-0.01 (-0.52 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
MEDAVAIL HOLDINGS INC
MEDAVAIL HOLDINGS INC
$0.39
$0.01 (1.32 %)
Finch Therapeutics Group Inc
Finch Therapeutics Group Inc
$0.50
$-0.01 (-2.13 %)
Humanigen Inc
Humanigen Inc
$0.23
$0.00 (2.06 %)
Immutep Ltd
Immutep Ltd
$1.90
$-0.01 (-0.52 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00